Stem definition | Drug id | CAS RN |
---|---|---|
4931 | 9002-60-2 |
Dose | Unit | Route |
---|---|---|
25 | U | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
July 3, 1950 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple sclerosis relapse | 104.72 | 19.59 | 63 | 5550 | 42901 | 50556610 |
Injection site bruising | 92.40 | 19.59 | 55 | 5558 | 36713 | 50562798 |
Product dose omission issue | 72.08 | 19.59 | 95 | 5518 | 183743 | 50415768 |
Therapy cessation | 55.33 | 19.59 | 35 | 5578 | 25976 | 50573535 |
Swelling face | 50.87 | 19.59 | 44 | 5569 | 52551 | 50546960 |
Blood glucose increased | 50.26 | 19.59 | 50 | 5563 | 71274 | 50528237 |
Epidural lipomatosis | 43.69 | 19.59 | 8 | 5605 | 105 | 50599406 |
Weight increased | 43.28 | 19.59 | 79 | 5534 | 201812 | 50397699 |
Fluid retention | 42.28 | 19.59 | 39 | 5574 | 50610 | 50548901 |
Infantile spasms | 38.67 | 19.59 | 8 | 5605 | 204 | 50599307 |
Magnetic resonance imaging head abnormal | 37.52 | 19.59 | 12 | 5601 | 1765 | 50597746 |
Cushingoid | 37.11 | 19.59 | 17 | 5596 | 6628 | 50592883 |
Insomnia | 35.66 | 19.59 | 67 | 5546 | 174798 | 50424713 |
Injection site discolouration | 30.26 | 19.59 | 15 | 5598 | 6959 | 50592552 |
COVID-19 | 29.73 | 19.59 | 31 | 5582 | 46631 | 50552880 |
Visual impairment | 26.22 | 19.59 | 35 | 5578 | 68240 | 50531271 |
Peripheral swelling | 24.93 | 19.59 | 64 | 5549 | 205872 | 50393639 |
Irritability | 23.92 | 19.59 | 22 | 5591 | 28404 | 50571107 |
Nail pigmentation | 22.42 | 19.59 | 5 | 5608 | 183 | 50599328 |
Increased appetite | 22.27 | 19.59 | 13 | 5600 | 8348 | 50591163 |
Appetite disorder | 20.34 | 19.59 | 11 | 5602 | 6103 | 50593408 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Infantile spasms | 56.82 | 27.99 | 10 | 1958 | 179 | 29572380 |
Fluid retention | 45.94 | 27.99 | 25 | 1943 | 23535 | 29549024 |
Blood glucose increased | 39.27 | 27.99 | 32 | 1936 | 58952 | 29513607 |
Irritability | 39.05 | 27.99 | 22 | 1946 | 22130 | 29550429 |
Multiple-drug resistance | 38.18 | 27.99 | 13 | 1955 | 3887 | 29568672 |
Weight increased | 37.73 | 27.99 | 35 | 1933 | 76632 | 29495927 |
Insomnia | 35.21 | 27.99 | 36 | 1932 | 88725 | 29483834 |
Drug ineffective | 32.49 | 27.99 | 73 | 1895 | 363097 | 29209462 |
Intramyelinic oedema | 31.70 | 27.99 | 4 | 1964 | 4 | 29572555 |
Swelling | 29.67 | 27.99 | 22 | 1946 | 35261 | 29537298 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Injection site bruising | 92.91 | 23.25 | 50 | 5380 | 36323 | 64456979 |
Product dose omission issue | 73.38 | 23.25 | 86 | 5344 | 194661 | 64298641 |
Multiple sclerosis relapse | 71.46 | 23.25 | 44 | 5386 | 41091 | 64452211 |
Blood glucose increased | 67.51 | 23.25 | 60 | 5370 | 98013 | 64395289 |
Therapy cessation | 67.49 | 23.25 | 39 | 5391 | 32450 | 64460852 |
Insomnia | 56.35 | 23.25 | 76 | 5354 | 197760 | 64295542 |
Fluid retention | 52.38 | 23.25 | 42 | 5388 | 59564 | 64433738 |
Irritability | 48.29 | 23.25 | 33 | 5397 | 36713 | 64456589 |
Weight increased | 46.20 | 23.25 | 72 | 5358 | 213276 | 64280026 |
Cushingoid | 46.09 | 23.25 | 19 | 5411 | 7584 | 64485718 |
Infantile spasms | 44.44 | 23.25 | 9 | 5421 | 274 | 64493028 |
Swelling face | 40.27 | 23.25 | 36 | 5394 | 59130 | 64434172 |
Magnetic resonance imaging head abnormal | 37.17 | 23.25 | 12 | 5418 | 2400 | 64490902 |
Intramyelinic oedema | 30.29 | 23.25 | 4 | 5426 | 5 | 64493297 |
Peripheral swelling | 30.11 | 23.25 | 59 | 5371 | 209094 | 64284208 |
Epidural lipomatosis | 29.56 | 23.25 | 8 | 5422 | 869 | 64492433 |
Multiple-drug resistance | 28.74 | 23.25 | 13 | 5417 | 6489 | 64486813 |
Drug ineffective | 28.17 | 23.25 | 142 | 5288 | 840105 | 63653197 |
Hypertension | 26.84 | 23.25 | 64 | 5366 | 259197 | 64234105 |
Visual impairment | 26.63 | 23.25 | 32 | 5398 | 74045 | 64419257 |
Increased appetite | 26.02 | 23.25 | 14 | 5416 | 10132 | 64483170 |
None
Source | Code | Description |
---|---|---|
ATC | H01AA01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ACTH |
FDA CS | M0000499 | Adrenocorticotropic Hormone |
CHEBI has role | CHEBI:33295 | diagnostic aid |
FDA EPC | N0000175941 | Adrenocorticotropic Hormone |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
West syndrome | indication | 28055006 | |
Stevens-Johnson syndrome | indication | 73442001 | DOID:0050426 |
Exacerbation of multiple sclerosis | indication | 192929006 |
Species | Use | Relation |
---|---|---|
Cats | Stimulation of the adrenal cortex where there is a general deficiency of ACTH | Indication |
Cattle | Stimulation of the adrenal cortex where there is a general deficiency of ACTH | Indication |
Cattle | Primary bovine ketosis | Indication |
Dogs | Diagnostic aid to test for adrenal dysfunction | Indication |
Dogs | Stimulation of the adrenal cortex where there is a general deficiency of ACTH | Indication |
Product | Applicant | Ingredients |
---|---|---|
Adrenomone | Dechra, Ltd. | 1 |
ACTH Gel | Bimeda Animal Health Limited | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.15 | acidic |
pKa2 | 3.37 | acidic |
pKa3 | 3.62 | acidic |
pKa4 | 3.86 | acidic |
pKa5 | 4.07 | acidic |
pKa6 | 4.31 | acidic |
pKa7 | 4.6 | acidic |
pKa8 | 9.43 | acidic |
pKa9 | 10.05 | acidic |
pKa10 | 12.25 | acidic |
pKa11 | 12.36 | acidic |
pKa12 | 12.63 | acidic |
pKa13 | 12.69 | acidic |
pKa14 | 12.93 | acidic |
pKa15 | 13.11 | acidic |
pKa16 | 13.11 | acidic |
pKa17 | 13.22 | acidic |
pKa18 | 13.41 | acidic |
pKa19 | 13.55 | acidic |
pKa20 | 13.6 | acidic |
pKa21 | 13.66 | acidic |
pKa22 | 13.75 | acidic |
pKa23 | 13.76 | acidic |
pKa24 | 13.79 | acidic |
pKa25 | 13.89 | acidic |
pKa26 | 14.0 | acidic |
pKa27 | 11.5 | Basic |
pKa28 | 11.26 | Basic |
pKa29 | 11.01 | Basic |
pKa30 | 10.81 | Basic |
pKa31 | 10.55 | Basic |
pKa32 | 10.3 | Basic |
pKa33 | 9.94 | Basic |
pKa34 | 7.62 | Basic |
pKa35 | 6.69 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Adrenocorticotropic hormone receptor | GPCR | AGONIST | UNKNOWN | IUPHAR | |||||
Melanocortin receptor 4 | GPCR | AGONIST | Ki | 6.16 | IUPHAR | ||||
Melanocortin receptor 3 | GPCR | AGONIST | Ki | 7.06 | IUPHAR | ||||
Melanocyte-stimulating hormone receptor | GPCR | AGONIST | Ki | 8.60 | IUPHAR | ||||
Adrenocorticotropic hormone receptor | GPCR | AGONIST | Kd | 9.80 | IUPHAR |
ID | Source |
---|---|
D00146 | KEGG_DRUG |
4018523 | VUID |
N0000146845 | NUI |
4018523 | VANDF |
4022410 | VANDF |
CHEBI:3892 | CHEBI |
CHEMBL1201610 | ChEMBL_ID |
3633 | IUPHAR_LIGAND_ID |
1366 | INN_ID |
9050-75-3 | SECONDARY_CAS_RN |
DB01285 | DRUGBANK_ID |
K0U68Q2TXA | UNII |
16132265 | PUBCHEM_CID |
2584471 | RXNORM |
2492 | MMSL |
326050 | MMSL |
4506 | MMSL |
4507 | MMSL |
84 | MMSL |
d00604 | MMSL |
002113 | NDDF |
002114 | NDDF |
126187000 | SNOMEDCT_US |
40789008 | SNOMEDCT_US |
C0001655 | UMLSCUI |
CHEMBL1201609 | ChEMBL_ID |
471 | INN_ID |
12427-33-7 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
1 Detoxification | HUMAN OTC DRUG LABEL | 81 | 55146-011 | LIQUID | 30 [hp_C] | ORAL | unapproved homeopathic | 9 sections |
Purified Cortrophin Gel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-860 | INJECTION | 80 [USPU] | INTRAMUSCULAR | NDA | 14 sections |
Acthar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63004-8710 | INJECTION | 80 [USPU] | INTRAMUSCULAR | NDA | 27 sections |
Acthar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63004-8710 | INJECTION | 80 [USPU] | INTRAMUSCULAR | NDA | 27 sections |